| 2933.99.06 | 00 | α-Butyl- α-(4-chlorophenyl)-1H-1,2,4- triazole-1- propanenitrile (Myclobutanil); and α-[2-(4-Chlorophenyl)ethyl]- α-phenyl-1H- 1,2,4-triazole-1-propanenitrile (Fenbuconazole) | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4¢/kg + 64.5% |
| 2933.99.08 | 00 | Acetoacetyl-5-aminobenzimidazolone; 3-(2H-Benzotriazol-2-yl)-5-(tert-butyl)-4- hydroxybenzene propanoic acid, C7-C9 branched or linear alkyl esters; 2-(2H-Benzotriazol-2-yl)-6-dodecyl-4- methyl phenol, in liquid form, branched and linear; and 1,3,3-Trimethyl-2-methyleneindoline | kg | Free | | 15.4¢/kg + 52% |
| 2933.99.12 | 00 | 6-Bromo-5-methyl-1H-imidazo[4,5-b]- pyridine; 2-sec-Butyl-4-tert-butyl-6-(benzotriazol-2- yl)phenol; 2-tert-Butyl-4-methyl-6-(5-chlorobenzotri- azol-2-yl)phenol; 2,4-Di-tert-butyl-6-(benzotriazol-2-yl)phenol; 2,4-Di-tert-butyl-6-(5-chlorobenzotriazol-2- yl)phenol; 2,3-Dichloro-6-quinoxalinecarbonyl chloride; 1-Hydroxy-2-carbazolecarboxylic acid; 2-Hydroxy-3-carbazolecarboxylic acid; 2-Hydroxy-3-carbazolecarboxylic acid, sodium salt; Iminodibenzyl(10,11-dihydro-5H-dibenz- [b,f]azepine); Indoline; 3-Methylbenzo[f]quinoline; 2-Methylindoline; 2-Methylmercaptobenzimidazole; 1-Methyl-2-phenylindole; 1-Methylpyrazine; 2,4-Methylpyrazolic acid; 2-Phenylbenzimidazole; 2-Phenylindole; Tetramethylpyrazine; 2,3,5-Triphenyltetrazolium chloride; dl-Tryptophan; and Vinylcarbazole, monomer | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4¢/kg + 39.5% |
| 2933.99.16 | 00 | o-Diquat dibromide (1,1'-Ethylene- 2,2'-dipyridylium dibromide) | kg | Free | | 15.4¢/kg + 40.5% |
| 2933.99.26 | 00 | Drugs: | | | | |
| 2933.99.51 | 00 | Cardiovascular drugs: | | | | |
| 2933.99.55 | 20 | Tolmetin sodium dihydrate | kg | | | |
| 2933.99.55 | 30 | Tolmetin sodium (anhydrous) | kg | | | |
| 2933.99.55 | | Drugs primarily affecting the central nervous system: | | | | |
| 2933.99.58 | 00 | Antidepressants, tranquilizers and other psychotherapeutic agents: | | | | |
| 2933.99.65 | 00 | Anticonvulsants, hypnotics and sedatives | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4¢/kg + 48.5% |
| 2933.99.79 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 52% |
| 2933.99.90 | 00 | Drugs | kg | 3.7% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX, P,SG) | 25% |
| 2934 | | Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: | | | | |
| 2934.10 | | Compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure: | | | | |
| 2934.10.10 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 52% |
| 2934.20 | | Compounds containing in the structure a benzothiazole ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2934.20.05 | 00 | N-tert-Butyl-2-benzothiazolesulfenamide | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX,P) 0.2¢/kg + 3.1% (SG) | 15.4¢/kg + 52% |
| 2934.20.15 | 00 | 2-Mercaptobenzothiazole; and N-(Oxydiethylene)benzothiazole-2-sulfenamide | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX,P) 0.2¢/kg + 3.1% (SG) | 15.4¢/kg + 52% |
| 2934.20.20 | 00 | 2-Mercaptobenzothiazole, sodium salt (2-Benzothiazolethiol, sodium salt) | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX,P) 2.8% (SG) | 15.4¢/kg + 40% |
| 2934.20.25 | 00 | 2-Amino-5,6-dichlorobenzothiazole; 2-(4-Aminophenyl)-6-methylbenzothiazole-7- sulfonic acid; 2-Amino-6-nitrobenzothiazole; and N,N-Dicyclohexyl-2-benzothiazolesulfenamide | kg | Free | | 15.4¢/kg + 52% |
| 2934.20.30 | 00 | 2-Amino-6-methoxybenzothiazole; 2-Amino-6-methylbenzothiazole; 6-Ethoxy-2-benzothiazolethiol; 3-Methylbenzothiazole-2-hydrazone; and Primuline base | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,L,MA,MX, P,SG) | 15.4¢/kg + 39.5% |
| 2934.20.40 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4¢/kg + 52% |
| 2934.30 | | Compounds containing in the structure a phenothiazine ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2934.30.12 | 00 | 2-(Trifluoromethyl)phenothiazine | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX, P,SG) | 15.4¢/kg + 45% |
Harmonized Tariff Schedule of the United States inquiry: gaming
